Biote Reports Second Quarter 2026 Financial Results
Biote reported second quarter revenue of $44.2 million, a decrease of 9.5% year-over-year, and swung to a net loss of $7.4 million compared to net income of $3.9 million in the prior year. The financial decline was primarily attributed to a voluntary product recall of hormone pellets shipped by Asteria Health, which negatively impacted procedure revenue and gross margins.
Key figures
- Revenue
- $44.2 million
- Guidance
- FY26 revenue above $175 million; Adjusted EBITDA above $25 million
- Revenue Yoy
- -9.5%
- Net loss
- $7.4 million
- Gross margin
- 65.4%
- Adjusted ebitda
- $5.6 million
- Procedure revenue
- $30.3 million
- Adjusted ebitda margin
- 12.6%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.